17 April 2023
John Ryder steps down as Chair of NZK
New Zealand King Salmon Investments Limited (NZX & ASX: NZK) announced that John Ryder has informed the Company of his intention to resign from his role as Chair. Mr Ryder’s resignation will take effect at the AGM on the 14th of June 2023.
Mr Ryder became a Director of New Zealand King Salmon in 2009. Reflecting on his time serving on the Board of New Zealand King Salmon, he said:
“It is the right time to leave NZKS, knowing the company is well-positioned for the future following the recovery from disruptions caused by the Covid-19 pandemic and mortality event at the back end of FY22 and start of FY23. The business has come a long way over the years, has an excellent team, a wonderful brand, and has created a sound platform for the continual expansion of earnings. The board is due for a refresh, and I wish to spend more time expanding my business activities with Qestral Corporation”.
Acting Chief Executive Graeme Tregidga said: “On behalf of New Zealand King Salmon I want to thank John for his many contributions to the company during his 14-year tenure.”
Mr Ryder was the joint founder and joint CEO of Ryman Healthcare Limited and is currently Executive Chair of Qestral Corporation and Independent Chair of Direct Capital VI Management Limited. Mr Ryder is a fellow of the New Zealand Institute of Accountants and was inducted into the New Zealand Business Hall of Fame in 2021.
The Board will commence a search for a new Chair.
Ends
Contact
Graeme Tregidga, Acting CEO, New Zealand King Salmon Investments Ltd,
[email protected]
Ben Rodgers, CFO and Company Secretary, New Zealand King Salmon Investments Ltd,
[email protected]
The S&P/NZX 50 Index closed at 12,809.59 points, down 87.36 points or 0.68%.
Genesis and Contact forked out millions to keep the lights on.
THL is targeting a $12m after-tax profit cost savings in the 2027 financial year.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details